Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

Marketwired August 26, 2013

Sarepta Therapeutics Announces Publication of Eteplirsen Clinical Study Results in the Annals of Neurology

Marketwired August 8, 2013

Sarepta Therapeutics Announces Second Quarter 2013 Financial Results and Recent Corporate Developments

Marketwired August 8, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ALNY, BCRX, ITMN and SRPT

Accesswire July 31, 2013

Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

Marketwired July 30, 2013

BBRY, MNKD, IRBT and SRPT added to NASDAQ Active Stock Watch List at GSR

Accesswire July 25, 2013

Sarepta Therapeutics to Announce Second Quarter 2013 Financial Results and Corporate Update on August 8, 2013

Marketwired July 25, 2013

Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy in First Half of 2014

Marketwired July 24, 2013

Sarepta Therapeutics to Host Conference Call to Discuss Regulatory Update for Eteplirsen on Wednesday, July 24, 2013

Marketwired July 23, 2013

Sarepta Therapeutics Announces At-the-Market Equity Offering Facility

Marketwired July 3, 2013

Sarepta Therapeutics to Present Company Overview at the JMP Securities Healthcare Conference

Marketwired July 2, 2013

Sarepta Therapeutics Announces Eteplirsen Demonstrates a Continued Benefit on Walking Test Through 84 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

Marketwired June 19, 2013

Sarepta Therapeutics to Present Company Overview at the Wells Fargo Securities 2013 Healthcare Conference

Marketwired June 5, 2013

Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments

Marketwired May 9, 2013

Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus

Marketwired May 7, 2013

Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013

Marketwired April 26, 2013

Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference

Marketwired April 18, 2013

Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes

Marketwired April 15, 2013

Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agreement for Exon-Skipping Program in Duchenne Muscular Dystrophy

Marketwired April 11, 2013

Pre-Market Analysis on Sarepta Therapeutics, BioMarin Pharma, Theravance, and Chelsea Therapeutics

PR Newswire April 8, 2013